Apollomics CEO granted 8,000 stock options
Apollomics’ CEO received new stock options, had RSUs vest into shares, and reports substantial indirect holdings through King Regent Management Limited.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Apollomics Inc. (APLM) reported that Chief Executive Officer and director Hung-Wen Chen had 5,000 Restricted Stock Units vest on September 15, 2026, converting into 5,000 Class A Ordinary Shares and bringing his directly held Class A shares to 423,334. On September 14, 2026, he also received a grant of 8,000 stock options with an exercise price of $23.18 per share, expiring on September 14, 2036, vesting in two equal installments on March 14, 2027 and September 14, 2027, subject to continued service. In addition, 1,029,695 Class A Ordinary Shares are held indirectly through King Regent Management Limited, over which he has voting and dispositive power but disclaims beneficial ownership except to the extent of his pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3, F4 | 5,000 | $0.00 | $0.00 |
| Exercise | CLASS A ORDINARY SHARES | 5,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F2 | 8,000 | $0.00 | $0.00 |
| holding | CLASS A ORDINARY SHARES F1 | -- | -- | -- |
Footnotes (4)
- F1. The reporting person is the sole director and shareholder of King Regent Management Limited and has voting and dispositive power over the shares held by King Regent Management Limited. Accordingly, Mr. Chen may be deemed to be the beneficial owner of such shares. Mr. Chen disclaims beneficial ownership of the securities held by King Regent Management Limited, except to the extent of his pecuniary interest therein.
- F2. The stock option was granted under the Apollomics Inc. 2023 Incentive Award Plan on September 14, 2026. The option vests and becomes exercisable over a one-year period: fifty percent (50%) of the shares subject to the option vest on March 14, 2027 (six months from the grant date), and the remaining fifty percent (50%) vest on September 14, 2027 (twelve months from the grant date), subject to the reporting person's continued service to the Issuer through each applicable vesting date.
- F3. Each restricted stock unit represents a contingent right to receive one Class A Ordinary Share.
- F4. RSUs were granted and previously reported on a Form 3 filed March 18, 2026 and a Form 3/A filed April 14, 2026. Of the initial RSU grant, 5,000 shares vested on each of February 9, 2026, March 15, 2026, June 15, 2026, and September 15, 2026. This transaction represents the vesting of 5,000 RSUs on September 15, 2026.
Key Figures
Key Terms
Restricted Stock Units financial
Stock Option (Right to Buy) financial
beneficial owner financial
pecuniary interest financial
Incentive Award Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Apollomics (APLM) CEO Hung-Wen Chen receive in this Form 4?
What indirect Apollomics (APLM) holdings are reported for the CEO?
What are the vesting terms of the 8,000 Apollomics (APLM) stock options granted to the CEO?
When do the newly granted Apollomics (APLM) stock options to the CEO expire?
Were the Apollomics (APLM) CEO’s transactions under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.